Clinical Trial Update: Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial investigating olanzapine for appetite loss in amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 2, Phase 3 | Status: COMPLETED